Cargando…

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

Oral squamous cell carcinoma (OSCC) is the most common type of cancer occurring in the oral and maxillofacial regions. Despite of the advances in the diagnosis and treatment, the overall 5-year survival rate has remained about 40%–50% in the past decades. Various nanotechnology-based carrier systems...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ran, Gao, Ruifang, Zhao, Yingjiao, Zhang, Fang, Wang, Xiangyu, Li, Bing, Wang, Lu, Ma, Lixin, Du, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382286/
https://www.ncbi.nlm.nih.gov/pubmed/35992794
http://dx.doi.org/10.3389/fonc.2022.930920
_version_ 1784769255190822912
author Li, Ran
Gao, Ruifang
Zhao, Yingjiao
Zhang, Fang
Wang, Xiangyu
Li, Bing
Wang, Lu
Ma, Lixin
Du, Jie
author_facet Li, Ran
Gao, Ruifang
Zhao, Yingjiao
Zhang, Fang
Wang, Xiangyu
Li, Bing
Wang, Lu
Ma, Lixin
Du, Jie
author_sort Li, Ran
collection PubMed
description Oral squamous cell carcinoma (OSCC) is the most common type of cancer occurring in the oral and maxillofacial regions. Despite of the advances in the diagnosis and treatment, the overall 5-year survival rate has remained about 40%–50% in the past decades. Various nanotechnology-based carrier systems have been investigated for their potentials in the OSCC treatment. However, because of the lack of active targeting of tumors, their application is limited. Studies have shown that gastrin-releasing peptide receptors (GRPRs) are overexpressed on many human cancers, including head and neck squamous cell carcinoma. Herein, we aimed to develop a GRPR-targeted nano-graphene oxide (NGO) nanoprobe drug delivery system for OSCC therapy. DOX@NGO-BBN-AF750 was synthesized by the non-covalent bonding method to couple carboxylated NGO with BBN-AF750 (bombesin antagonist peptides conjugated to Alexa Fluor 750) and DOX (doxorubicin) through π-π and hydrogen bonding. Internalization and antitumor activities were carried out in human HSC-3 cancer cells. The tumor pH microenvironment was simulated to study the release of antitumor drug DOX from the DOX@NGO-ant BBN-AF750 complex under different pH conditions. DOX@NGO-BBN-AF750 showed internalization into HSC-3 cells. The IC50 (50% inhibitory concentration) was 5 µg/ml for DOX@NGO-BBN-AF750 in HSC-3 cells. Furthermore, DOX@NGO-BBN-AF750 showed a pH-sensitive drug release rate, and a dose-dependent and pH-responsive cytotoxicity in HSC-3 cells. DOX@NGO-BBN-AF750 presents the characteristics ensuring a slow release of DOX from the nanoprobe, thereby protecting the drug from degradation and prolonging the half-life of the drug. This report provides a versatile strategy to achieving targeted and imaging-guided therapy of OSCC.
format Online
Article
Text
id pubmed-9382286
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93822862022-08-18 pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy Li, Ran Gao, Ruifang Zhao, Yingjiao Zhang, Fang Wang, Xiangyu Li, Bing Wang, Lu Ma, Lixin Du, Jie Front Oncol Oncology Oral squamous cell carcinoma (OSCC) is the most common type of cancer occurring in the oral and maxillofacial regions. Despite of the advances in the diagnosis and treatment, the overall 5-year survival rate has remained about 40%–50% in the past decades. Various nanotechnology-based carrier systems have been investigated for their potentials in the OSCC treatment. However, because of the lack of active targeting of tumors, their application is limited. Studies have shown that gastrin-releasing peptide receptors (GRPRs) are overexpressed on many human cancers, including head and neck squamous cell carcinoma. Herein, we aimed to develop a GRPR-targeted nano-graphene oxide (NGO) nanoprobe drug delivery system for OSCC therapy. DOX@NGO-BBN-AF750 was synthesized by the non-covalent bonding method to couple carboxylated NGO with BBN-AF750 (bombesin antagonist peptides conjugated to Alexa Fluor 750) and DOX (doxorubicin) through π-π and hydrogen bonding. Internalization and antitumor activities were carried out in human HSC-3 cancer cells. The tumor pH microenvironment was simulated to study the release of antitumor drug DOX from the DOX@NGO-ant BBN-AF750 complex under different pH conditions. DOX@NGO-BBN-AF750 showed internalization into HSC-3 cells. The IC50 (50% inhibitory concentration) was 5 µg/ml for DOX@NGO-BBN-AF750 in HSC-3 cells. Furthermore, DOX@NGO-BBN-AF750 showed a pH-sensitive drug release rate, and a dose-dependent and pH-responsive cytotoxicity in HSC-3 cells. DOX@NGO-BBN-AF750 presents the characteristics ensuring a slow release of DOX from the nanoprobe, thereby protecting the drug from degradation and prolonging the half-life of the drug. This report provides a versatile strategy to achieving targeted and imaging-guided therapy of OSCC. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9382286/ /pubmed/35992794 http://dx.doi.org/10.3389/fonc.2022.930920 Text en Copyright © 2022 Li, Gao, Zhao, Zhang, Wang, Li, Wang, Ma and Du https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Ran
Gao, Ruifang
Zhao, Yingjiao
Zhang, Fang
Wang, Xiangyu
Li, Bing
Wang, Lu
Ma, Lixin
Du, Jie
pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy
title pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy
title_full pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy
title_fullStr pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy
title_full_unstemmed pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy
title_short pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy
title_sort ph-responsive graphene oxide loaded with targeted peptide and anticancer drug for oscc therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382286/
https://www.ncbi.nlm.nih.gov/pubmed/35992794
http://dx.doi.org/10.3389/fonc.2022.930920
work_keys_str_mv AT liran phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy
AT gaoruifang phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy
AT zhaoyingjiao phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy
AT zhangfang phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy
AT wangxiangyu phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy
AT libing phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy
AT wanglu phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy
AT malixin phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy
AT dujie phresponsivegrapheneoxideloadedwithtargetedpeptideandanticancerdrugforoscctherapy